Anika Therapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stephen D. Griffin
- Full Time Employees
- 288
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 32 Wiggins Avenue Bedford MA United States of America 01730
- IPO Date
- May 3, 1993
- CIK
- 0000898437
- Website
- anikatherapeutics.com
- Similar Companies
- Business
- Anika Therapeutics, Inc. is a global joint preservation company specializing in early intervention orthopedic care. The company develops, manufactures, and commercializes therapeutic products designed for osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. Its core product portfolio is based on its proprietary hyaluronic acid (HA) technology platform, including OA pain management injectables such as Monovisc and Orthovisc, and the next-generation single-injection product Cingal, which combines cross-linked HA with a steroid. Anika’s regenerative solutions include the Integrity Implant System, an HA-based scaffold for rotator cuff and tendon repairs, as well as other orthopedic implants and instruments like the X-Twist Fixation System. The company also markets advanced shoulder arthroplasty systems supported by preoperative planning software. Founded in 1996 and headquartered in Bedford, Massachusetts, Anika operates globally with a significant presence in the United States and international markets. The company targets orthopedic surgeons, sports medicine specialists, and healthcare providers focusing on joint preservation and repair. Recent major changes include the strategic divestiture of the Arthrosurface business in October 2024 and the completed sale of Parcus Medical to Medacta Group SA in March 2025, enabling Anika to concentrate fully on its core hyaluronic acid technology and expanding Regenerative Solutions portfolio. Additionally, in 2024, Anika launched several new products including the Integrity Implant System and X-Twist Fixation System, and advanced its FDA regulatory filings for Hyalofast, a proprietary HA scaffold for cartilage repair with U.S. market launch anticipated by 2026. The company’s strategic focus is on profitable growth through its HA-driven OA pain management products and high growth regenerative solutions. Anika Therapeutics leverages a technology-driven approach within the healthcare equipment and supplies industry, dedicating resources to innovation in minimally invasive orthopedic products and early intervention treatments, positioning itself as a leader in joint preservation and restoring active mobility worldwide.
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bullish On Anika Therapeutics's Pullback As Integrity Scales
Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript
Anika Reports First Quarter 2026 Financial Results
Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
Is Anika Therapeutics Inc (ANIK) a Bargain After 3.1% Drop? GF Value Says Undervalued
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Top 2 Health Care Stocks That May Crash This Quarter
Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript
Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates
Anika Reports Fourth Quarter and Full Year 2025 Financial Results
Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving Average – Here’s What Happened
Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference
Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026
ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders
ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.
ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP
Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK
Connor Clark & Lunn Investment Management Ltd. Acquires 8,573 Shares of Anika Therapeutics Inc. $ANIK
Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript